ArticlePloS one2025
Alpinetin protects against iron overload related osteoarthritis via NRF2/HO-1 pathway.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAlpinetin(APT) is a natural product with anti-inflammatory and antioxidant effects. Iron overload has been recognized in recent years as a new way to exacerbate osteoarthritis.
objectiveThis study evaluated the effects of ATP on iron overload related osteoarthritis. MATERIALS AND
methodsC57BL/6J mice were randomly allocated to five groups as follows (n = 10 mice each): (1) sham; (2) destabilized medial meniscus(DMM); (3) DMM + ID; (4) DMM + ID + APT-L (50 mg/kg APT gavage daily); (5) DMM + ID + APT-H (100 mg/kg APT gavage daily). The chondrocytes treated by FAC (100μM) were used as an in vitro model of iron overload and the effect of APT was observed. Flow cytometry, fluorescence microscopy, Western blot, qRT-PCR and micro-CT were used to detect the mechanism of action of the APT.
resultOur studies showed that APT improved the viability of chondrocytes induced by iron overload. APT can reduce apoptosis of chondrocytes (19.41 ± 2.12% vs. 9.82 ± 1.74%). Furthermore, APT was found significantly attenuated ROS accumulation (2.04 ± 0.31 vs. 1.44 ± 0.15-fold) of chondrocytes through upregulating antioxidant genes NRF2 (1.18 ± 0.13 vs. 1.55 ± 0.17-fold) and HO-1 (1.27 ± 0.15 vs. 1.77 ± 0.20-fold). In vivo experiments revealed that APT attenuated cartilage damage (OARSI score 5.75 ± 1.32 vs. 3.75 ± 0.96) and subchondral bone proliferation in iron overload osteoarthritis mice.
conclusionsOur results show that APT can attenuate iron overload-induced cartilage damage in vivo and in vitro via the NRF2/HO-1 pathway. We demonstrated for the first time that APT has promising applications in iron overload diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.